Story perspectives

New Plasma Biomarkers Revolutionize Alzheimer's Diagnosis in Latin America

9/9/2025

Summary

Story summary

Plasma biomarkers, especially p-tau217, show promise for diagnosing Alzheimer's across various populations.
Tailored diagnostic criteria for Alzheimer's are necessary in Latin America to address health disparities.
Cognitive reserve may affect clinical progression in Alzheimer's, indicating a complex relationship.
Dementia prevalence is increasing in middle-income countries, impacting healthcare systems significantly.
Research on blood-brain barrier integrity could improve the diagnostic accuracy of plasma amyloid-? for Alzheimer's.

1 of 1

Story summary

Plasma biomarkers, especially p-tau217, show promise for diagnosing Alzheimer's across various populations.
Tailored diagnostic criteria for Alzheimer's are necessary in Latin America to address health disparities.
Cognitive reserve may affect clinical progression in Alzheimer's, indicating a complex relationship.
Dementia prevalence is increasing in middle-income countries, impacting healthcare systems significantly.
Research on blood-brain barrier integrity could improve the diagnostic accuracy of plasma amyloid-? for Alzheimer's.